Trials / Completed
CompletedNCT05683912
Aflibercept for Diabetic Macular Edema In Real-life Practice in GREece
Aflibercept for Diabetic Macular Edema In Real-life Practice in GREece: The ADMIRE Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (actual)
- Sponsor
- University of Athens · Academic / Other
- Sex
- All
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
ADMIRE was a prospective, observational cohort study of patients with diabetic macular edema (DME). Efficacy was assessed by change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to months 12, 24 and 36 after treatment with intravitreal aflibercept in treatment-naïve patients and previously treated patients. Safety was evaluated by recording any patients-reported events.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aflibercept | Intravitreal aflibercept as used in the routice clinical practice |
Timeline
- Start date
- 2019-09-01
- Primary completion
- 2021-09-01
- Completion
- 2022-12-15
- First posted
- 2023-01-13
- Last updated
- 2023-01-13
Locations
1 site across 1 country: Greece
Source: ClinicalTrials.gov record NCT05683912. Inclusion in this directory is not an endorsement.